Liquid Biopsy - TLDx
NGS DNA panel - non invasive

591 genes NGS non invasive DNA panel, focused on key tumor-associated mutations for a fast and accurate tumor profiling from plasma cell-free DNA (cfDNA)
This panel is designed to provide clinical decision support for patients with solid tumor and is focused on the identification of oncologic mutations

+600 cancer-relevant genomic regions screened including

  • Frequently mutated genes such as BRAF, KRAS, EGFR, PIK3CA, HER2 and TP53.
  • SNPs detection: Single Nucleotide Polymorphisms
  • InDels detection: Insertions and Deletions
  • CNVs detection: Copy Number Variations
  • Gene fusions detection between covered genes plus 22 additional cancer-specific gene fusions
  • TMB: Determination of Tumor Mutational Burden status

Order now
TLDx indications
OmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial Inteligence



Non invasive screening for clinically relevant tumor-associated mutations

Therapeutic Solutions

Identification of therapeutic solutions for cancer patients not able to have their tumor biospsied


Monitoring cancer response, and detection of resistance mechanisms

Technical Overview

Includes clinically relevant genes and biomarkers for following cancer types

Full list of 591 genes and other DNA alterations in this panel here